Daily Ards Research Analysis
Three studies collectively advance ARDS/ALI science and care: a mechanistic paper links obesity to worsened lung injury via a GFI1–ACOD1–Nrf2 axis in alveolar macrophages; a small multicenter randomized trial finds nebulised heparin safe but ineffective and associated with worse oxygenation in COVID-19 ARDS; and a multicenter ECMO cohort identifies Enterococcus-dominant bloodstream infections, supporting empiric vancomycin plus broad Gram-negative coverage.
Summary
Three studies collectively advance ARDS/ALI science and care: a mechanistic paper links obesity to worsened lung injury via a GFI1–ACOD1–Nrf2 axis in alveolar macrophages; a small multicenter randomized trial finds nebulised heparin safe but ineffective and associated with worse oxygenation in COVID-19 ARDS; and a multicenter ECMO cohort identifies Enterococcus-dominant bloodstream infections, supporting empiric vancomycin plus broad Gram-negative coverage.
Research Themes
- Immunometabolic mechanisms in obesity-linked ALI/ARDS
- Inhaled anticoagulants in COVID-19 ARDS
- Empiric antimicrobial strategy for ECMO bloodstream infection
Selected Articles
1. Elevated GFI1 in Alveolar Macrophages Suppresses ACOD1 Expression and Exacerbates Lipopolysaccharide-Induced Lung Injury in Obesity.
This mechanistic study links obesity to aggravated ALI via suppression of ACOD1 in alveolar macrophages, driven by elevated GFI1 and modulated through Nrf2 signaling. ACOD1 overexpression was protective, while its knockdown worsened injury, highlighting the itaconate/Nrf2 pathway as a candidate therapeutic axis.
Impact: It uncovers a previously unappreciated GFI1–ACOD1–Nrf2 immunometabolic pathway driving obesity-aggravated lung injury, offering testable targets for ARDS/ALI.
Clinical Implications: While preclinical, findings support exploring ACOD1/itaconate augmentation or GFI1 inhibition and Nrf2 activation as macrophage-targeted strategies in obese patients at risk of ALI/ARDS.
Key Findings
- ACOD1 expression is significantly decreased in lung tissue and alveolar macrophages from obese (HFD) mice and clinical samples.
- ACOD1 knockdown exacerbates lung injury, inflammation, and oxidative stress; overexpression mitigates these effects.
- Nrf2 inhibition attenuates the protective effects of ACOD1 overexpression in obesity-aggravated ALI.
- GFI1 protein is elevated in alveolar macrophages in obesity; GFI1 knockdown upregulates ACOD1.
Methodological Strengths
- Integrated human and mouse data with transcriptomics and functional validation.
- In vivo and in vitro manipulation (knockdown/overexpression) with pathway interrogation via Nrf2 inhibition.
Limitations
- Preclinical study with limited direct clinical endpoints.
- Sample sizes and comprehensive data-sharing details are not specified in the abstract.
Future Directions: Evaluate pharmacologic activation of ACOD1/itaconate and Nrf2, or GFI1 inhibition, in obese ALI/ARDS models and pilot translational studies; define macrophage-targeted delivery strategies.
To investigate the mechanisms behind the worsening of acute lung injury (ALI) in obesity, transcriptomic sequencing is performed, and significantly reduced mRNA levels of Aconitate Decarboxylase 1 (ACOD1) in the lung tissue of high-fat diet (HFD) mice are found. Clinical samples are collected, an ALI model is established in HFD mice, and both human and mouse samples are analyzed, revealing a significant decrease in ACOD1 expression in lung tissue and alveolar macrophages in obesity. Further in vivo and in vitro experiments show that ACOD1 knockdown worsens lung injury, inflammation, and oxidative stress, while ACOD1 overexpression alleviates these effects. Moreover, nuclear factor erythroid 2-related factor 2 (Nrf2) inhibition diminishes the protective effects of ACOD1 overexpression in ALI exacerbated by obesity. Additionally, in the context of obesity, growth factor independent 1 (GFI1) protein levels are elevated in alveolar macrophages, and its knockdown leads to upregulated ACOD1 expression. Therefore, this study suggests that ACOD1 downregulation in alveolar macrophages is a key factor in worsening ALI in obesity, likely driven by GFI1 upregulation.
2. Can nebulised heparin reduce acute lung injury in patients with SARS‑CoV‑2 requiring advanced respiratory support in Ireland: the CHARTER‑Ireland phase Ib/IIa, randomised, parallel-group, open-label study.
In this multicenter randomized open-label phase Ib/IIa trial (n=40), nebulised unfractionated heparin did not reduce D-dimer over 10 days and was associated with worse oxygenation in COVID-19 ARDS, despite an acceptable safety profile without severe bleeding or HIT.
Impact: Provides prospective randomized evidence against nebulised heparin for COVID-19 ARDS, cautioning against off-label use and guiding future trial designs.
Clinical Implications: Nebulised unfractionated heparin should not be used routinely in COVID-19 ARDS outside trials, given lack of biomarker benefit and worsened oxygenation; careful monitoring for bleeding remains prudent.
Key Findings
- No significant reduction in D-dimer from baseline to day 10 with nebulised heparin versus standard care (p=0.996).
- Acceptable safety profile: more bleeding events in the heparin group but no pulmonary bleeding, severe hemorrhage, or HIT.
- Patients receiving heparin had worse oxygenation indices (lower PaO2/FiO2).
Methodological Strengths
- Multicenter randomized controlled design with prespecified biomarker and safety co-primary outcomes.
- Clear reporting of adverse events including bleeding and thrombocytopenia.
Limitations
- Open-label design with small sample size (n=40) likely underpowered for clinical outcomes.
- COVID-19-specific context and surrogate primary endpoint (D-dimer) limit generalizability to non-COVID ARDS and hard outcomes.
Future Directions: Conduct adequately powered, blinded RCTs testing inhaled anticoagulants with hard clinical endpoints and stratification by thrombosis phenotype; evaluate non-COVID ARDS populations.
BACKGROUND: Nebulised unfractionated heparin may attenuate COVID-19 ARDS by reducing pulmonary microvascular thrombosis, blocking SARS-CoV-2 entry into cells, and decreasing lung inflammation. COVID-19 patients with a raised D-dimer have areas of pulmonary hypoperfusion on CT perfusion scans of the lung and have increased mortality risk. METHODS: This was a phase Ib/IIa open-label multi-centre, randomised controlled trial. The study was designed to evaluate whether nebulised unfractionated heparin decreased D-dimer concentrations, with safety as a co-primary outcome. RESULTS: Forty patients were recruited, with 20 patients into each group. Mean age was 56.6 (SD 11.5) in the heparin group and 51.3 (SD 14.7) in the standard care group, while 60% of participants were male. There was no change in D-dimers from baseline to day 10 (heparin group mean change - 316.5, [SD 1840.3] and control group mean change - 321.7 [SD 3589.4]; p = 0.996). Fourteen patients suffered at least one serious adverse event, 9 patients the Heparin group and 5 in the control group. Eight patients had one or more bleeding events, 5 in the heparin group and 3 in the control group, but were no cases of pulmonary bleeding, of severe haemorrhage or of heparin-induced thrombocytopenia. Patients receiving heparin therapy had lower PaO CONCLUSIONS: Nebulised unfractionated heparin was safe and well tolerated, but did not reduce D-dimer concentrations, and worsened oxygenation indices in patients with COVID-19 ARDS.
3. Which antimicrobial treatment for patients with bloodstream infection during ECMO support?
In a 12-ICU retrospective cohort (n=182) of ECMO patients with BSI of unknown source, Enterococcus species were most common (37.4%). Empiric coverage with vancomycin plus piperacillin/tazobactam or a carbapenem would have been appropriate in most cases, whereas third-generation cephalosporins alone were frequently inadequate.
Impact: Offers pragmatic, multicenter susceptibility data to guide empiric antimicrobial selection for ECMO-associated BSI, a common complication among ARDS patients requiring extracorporeal support.
Clinical Implications: For ECMO patients with suspected BSI of unknown source, empiric therapy should include vancomycin plus piperacillin/tazobactam or a carbapenem to cover Enterococcus and ESBL-producing Enterobacterales; avoid third-generation cephalosporin monotherapy.
Key Findings
- Enterococcus species accounted for 37.4% of BSIs during ECMO, followed by Enterobacterales (26.9%).
- Multidrug-resistant organisms were implicated in 14.3% of cases, mainly ESBL-producing Enterobacterales.
- Empiric vancomycin plus piperacillin/tazobactam (85.2% appropriate) or vancomycin plus a carbapenem (92.3% appropriate) covered most isolates; only 32.4% were susceptible to third-generation cephalosporins.
Methodological Strengths
- Multicenter design across 12 ICUs focusing specifically on ECMO-associated BSI of unknown source.
- Detailed microbiology with appropriateness of empiric regimens quantified.
Limitations
- Retrospective observational design without randomized comparisons or outcome-adjusted analyses.
- Limited to European centers and unknown-source BSIs; clinical outcome impacts (e.g., mortality) not detailed.
Future Directions: Prospective validation of empiric protocols in ECMO BSIs, integration of ECMO pharmacokinetics, and impact on outcomes; antimicrobial stewardship with de-escalation strategies.
OJECTIVE: We aim to describe a large, multicenter cohort of patients with bloodstream infection (BSI) acquired during extracorporeal membrane oxygenation (ECMO) support. METHODS: We conducted a retrospective observational study in 12 Europeans ICUs. Only patients who developed a BSI of unknown source during ECMO support were included in the present analysis. Primary aim was to describe BSI epidemiology in patients with ECMO support. Secondary objectives were to describe antimicrobial susceptibility of incriminated micro-organisms. RESULTS: One hundred and eighty-two patients were included. Main reason for ECMO support was ARDS, followed by cardiogenic shock and post-cardiotomy. Half of the patients (51.9%) received early antimicrobial therapy. Main incriminated microorganisms were Enterococcus sp. (37.4%), Enterobacterales (26.9%), coagulase negative Staphylococci (15.9%) and Gram negative bacilli (11.5%). Multi drug resistant organisms (MDRO) were incriminated in 26 (14.3%) BSI and were mainly extended spectrum producing-Enterobacterales (17/26). Antimicrobial therapy was considered as appropriate in 130 patients (71.4%). Patients who received inappropriate antimicrobial therapy were more frequently infected with MDRO. Only 59 (32.4%) of cases were susceptible to 3rd generation cephalosporin while association of piperacillin/tazobactam with vancomycin was considered appropriate in 155 cases (85.2%) as compared with 168 cases (92.3%) for carbapenems combined with vancomycin. CONCLUSION: Enterococcus sp. was incriminated in about a third of BSI among patients with ECMO support. High appropriateness would only be obtained with piperacilline/tazobactam or carbapenems in association with vancomycin while 3rd generation cephalosporin would have failed in the majority of BSI cases. CLINICAL TRIAL NUMBER: Not applicable.